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Antibodies against the 65-kDa isoform of glutamic acid
decarboxylase (GAD65) can be applied as a predictive tool
for childhood type-1 diabetes (1–6) and to facilitate the
differential diagnosis of diabetes in adults (7–9). How-
ever, the sensitivity and specificity of GAD antibody
screening have not been fully characterized, and the
positive predictive value of screening varies from 20% to
70%, depending on the strategy applied and the popula-
tion studied (2, 3, 5–7, 9–12). The current study aims to
identify factors that may lead to false-positive results in
GAD antibody screening.
Previously, it has been demonstrated that the GAD
antibody frequency in mixed connective tissue disease
and stiff-man syndrome is increased, although not all
patients who suffer from these diseases and are positive
for GAD antibodies develop type-1 diabetes (13, 14).
GAD is expressed in the islets of Langerhans, neuronal
tissue, the ovaries, and the testes (15, 16). Similar to the
above-mentioned examples, comorbidity involving these
tissues may lead to GAD antibody formation but not
to diabetes. Therefore, we compared the prevalence of
GAD antibodies in patients with cystic fibrosis, epilepsy,
Guillain-Barre´ syndrome, and premature ovarian failure
to the prevalence in an unselected population of 1403
schoolchildren.
In addition, thresholds for positivity for GAD antibod-
ies have generally been defined in children. These thresh-
olds might not be applicable when testing for type-1
diabetes in adults. Therefore, we studied whether GAD
antibody concentrations are correlated to age and sex, and
whether adjustment of assay thresholds to include these
variables may improve screening specificity.
The frequencies of positive results for GAD antibodies
and the concentrations of GAD antibodies were estab-
lished in a population of 1403 schoolchildren, ages 10–12
years, without chronic diseases (17 ). During a 10-year
follow-up, two of these children developed type-1 diabe-
tes [ascertainment .96% (18 )].
The influence of comorbidity on GAD antibody concen-
trations and the frequencies of positive results were
studied in four patient populations. The subjects included
394 patients who participated in the Dutch study of
epilepsy in childhood (19, 20). These patients were eligi-
ble for the current study if the diagnosis was confirmed
on the basis of electroencephalograms or therapy and
sufficient serum for antibody analysis was available. Sera
collected within 2 months after the presenting seizure
(mean duration, 0.7 months; n 5 228) and at the longest
disease duration available of each patient (mean duration,
12.2 months; range, 2–50 months; n 5 294) were analyzed
separately. The diagnosis and development of diabetes
during follow-up (5 years) were recorded from the med-
ical records. Forty-three serum samples from 38 cystic
fibrosis patients (collected in 1990–1992) were analyzed
for GAD antibodies. In addition, we studied 30 patients
with premature ovarian failure and 28 patients with
Guillain-Barre´ syndrome (14 males; age range, 19–64
years). All patient sera were stored at 280 °C.
The influence of age and sex on GAD antibody concen-
trations and the frequencies of positive results were
studied in 1287 individuals from the city of Zoetermeer,
who participated in a study of cardiovascular risk factors.
Sera were collected in 1976 and stored at 220 °C until
testing. The population is described in detail elsewhere
(21 ). The demographic data of the populations are shown in
Table 1.
The study protocols were approved by the appropriate
medical ethics committees according to the Helsinki Dec-
laration. Informed consent was obtained from all partici-
pants or their parents.
Sera were tested for GAD antibodies by radiobinding
assay (RBA) (13 ) or immunoprecipitation and sodium
dodecyl sulfate-polyacrylamide gel electrophoresis of the
Triton X-100 fraction of [35S]methionine-labeled fetal rat
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islets (a gift from Dr. T. Dyrberg and H. Richter-Olesen,
the Hagedorn Research Institute, Gentofte, Denmark) and
evaluated using autoradiography [conventional immuno-
precipitation (cIMP)] (22 ) as indicated in Table 1.
For the RBA, all sera were analyzed in triplicate, and
precipitated radioactivity was counted in a microbeta
plate reader (EG&G Wallac). Internal reference sera were
included in each plate for the epilepsy and cystic fibrosis
patients and in each third plate for the schoolchildren and
the general population. These internal reference sera were
used to calculate an index (GAD index) for the purpose of
comparison of experiments (13 ). The GAD antibody con-
centration in the positive reference serum was in the
linear range of the dilution curve, which allowed the GAD
index to be interpreted semiquantitatively. The threshold
for positivity was defined as the 99.5th centile of the
population of schoolchildren (GAD index .0.21).
The statistical package SPSS for Windows (SPSS) was
used for data analysis. The x2, Mann–Whitney, and
Kruskal–Wallis tests were used to analyze differences
between groups. Trends within groups were analyzed by
the Spearman correlation test.
The GAD antibody frequencies of positive results and
concentrations in the six populations studied are shown in
Table 1. The positive individuals did not differ from the
negative individuals in age or sex distribution in any of
the populations studied. The GAD antibody concentra-
tions and frequencies of positive results in the patient
populations were not significantly increased compared
with the schoolchildren.
In the epilepsy patients, the GAD antibody positive
frequency shortly after the presenting seizure did not
differ from the frequency at long disease duration, nor
was there a correlation between antibody concentra-
tions or positive frequencies and duration of epilepsy.
Two children from the epilepsy cohort developed dia-
betes during follow-up. One was positive for GAD
antibodies in a sample taken before diabetes onset (at
the presenting seizure) and 7 months after onset of
diabetes (13-month epilepsy duration). The other was
negative for GAD antibodies in all serum samples
analyzed. Two other patients were positive for GAD
antibodies (in only one sample) but did not develop
diabetes during follow-up.
One of the cystic fibrosis patients had a GAD index of
0.21, which is just at the defined threshold for positivity.
A serum sample from this patient collected 3 months later
was negative (GAD index, 0.16). Two out of five school-
children who were positive for GAD antibodies devel-
oped diabetes during follow-up.
As shown in Fig. 1, there was a slight but statistically
significant correlation between age and GAD index
(Spearman correlation coefficient, 0.161; P ,0.001). In
addition, the GAD index in women was significantly
higher than in men (P 5 0.009; median GAD index, 0.043
and 0.037, respectively). The correlation between sex and
GAD index did not explain the correlation with age and
vice versa.
To study whether the observed correlation with age
affected threshold definition, the general population was
split into 10 similarly sized age groups (Fig. 1). The
threshold for positivity was adjusted to the 99.5th centile
of each age group and compared with the 99.5th centile
threshold of the general population (0.68; see Fig. 1) and
the threshold established in the schoolchildren. This
yielded four additional positive individuals. One of these
was negative at the initially applied threshold of 0.21. One
individual who was positive at the general population
threshold was negative when the age-adjusted thresholds
were applied. Adjustment of thresholds for sex did not
affect the antibody frequencies.
Strikingly, the GAD index was significantly higher in
the general population than in the schoolchildren cohort.
This difference remained present when outliers were
discarded from both populations. To exclude that this
observation was attributable to age effects, we selected all
individuals 10–12 years of age from the general popula-
tion and compared their GAD index to the GAD index in
the schoolchildren cohort. The median GAD index in this
selection of the general population (0.01) was still signif-
icantly higher than in the schoolchildren cohort (20.04).
Table 1. Demographic data of populations tested for GAD antibodies.
Population Schoolchildren General population Epilepsy, all Epilepsy, onset
Epilepsy, long
duration Cystic fibrosis
Premature
ovarian
failure
Guillain-
Barre´
syndrome
n 1403 1287 522 228 294 43 30 28
Age range (mean),
years
10–12 6–86 (32) 6–19 (6.42) 0–14 (5.77) 1–19 (6.87) 19–64
Disease duration
(mean), months
NAa NA 0–50 (6.9) 0–1.5 (0.23) 2–50 (12)
Median GAD index
(range)
20.01
(20.05 to 1.53)
0.04b
(20.07 to 1.71)
0.01
(20.1 to 1.45)
0.01
(20.1 to 1.45)
0.02
(20.1 to 0.28)
20.05
(20.08 to 0.21)
Positive RBA
(n), %
0.4 (5) 1.0 (13) 0.8 (4) 0.9 (2) 0.6 (2) 2.3 (1) NT NT
Positive cIMP, n 5 NT 4 2 2 NT 0 1
cIMP/RBA RBA/cIMP RBA RBA/cIMP RBA/cIMP RBA/cIMP RBA cIMP cIMP
a NA, not applicable; NT, not tested.
b P ,0.001 compared with the schoolchildren.
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None of the diseases involving tissues expressing GAD
evaluated in the current study caused a significant in-
crease of GAD antibody concentrations or frequencies of
positive results. One might argue that the use of different
methods for antibody detection in the patients and refer-
ence populations weakens the comparative analysis.
However, by evaluation of all epilepsy patients and the
schoolchildren who had GAD antibody concentrations
higher than the mean 1 1 SD in cIMP, we demonstrated
that cIMP is at least as sensitive or possibly more sensitive
than the RBA (data not shown). In the current study, we
hypothesized that the GAD antibody frequency of posi-
tive results in neuroendocrine patients was higher be-
cause of non-diabetes-associated formation of GAD anti-
bodies. Using the highly sensitive immunoprecipitation
technique in the patient populations would only magnify
this effect.
One of 28 (3.6%) Guillain-Barre´ syndrome patients was
positive for GAD antibodies. These data clearly suggest
that GAD antibodies are not part of the Guillain-Barre´
syndrome, but additional studies are needed to draw
definite conclusions.
We observed a slight, but statistically significant, posi-
tive correlation between age and GAD index, but this
correlation was not reflected in threshold definition. Ex-
clusion of outliers from the distribution did not alter these
perspectives. Although we observed a difference in the
mean GAD index between males and females, this did not
Fig. 1. Correlation between age and GAD antibody concentrations in 1287 individuals from the general population.
Spearman correlation coefficient, 0.161; P ,0.001. Dotted lines indicate the applied threshold (0.21) and the population-adjusted threshold (0.68).
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affect threshold definition. These results are in concor-
dance with the observations from a previous study in a
substantially smaller population (23 ) and indicate that
adjustment of assay thresholds for age or sex is not
indicated.
The GAD index in the general population was signifi-
cantly increased compared with the schoolchildren. We
concluded that this difference was attributable to differ-
ences in age between the populations. In addition, both
populations were tested in one experiment (using one
batch of tracer, control sera, and protein A-Sepharose),
thus excluding technical variation of the methods used. A
noticeable difference between both populations was se-
rum storage. The general population sera were stored at
220 °C for 16 years in tubes with snap caps. When
defrosted, some of these sera contained precipitates,
which were removed by centrifugation before GAD anti-
body analysis. The sera of the schoolchildren cohort, on
the contrary, were stored at 280 °C for 10 years in tubes
with screw caps and had never been defrosted before the
GAD antibody analysis. It is possible that the storage
conditions of the samples from the general population led
to the observed increased antibody concentrations in the
general population sera. This observation implies that
storage conditions should be monitored carefully to ex-
clude such technical problems in future studies. Because
all sera from the general population were stored in one
freezer in identical tubes for the same period of time, it is
not likely that the storage conditions affected the analysis
of age and sex effects in the general population. In
addition, positive samples did not differ in macroscopic
aspects from negative samples.
This study demonstrates that age- and sex-nondefined
populations can be used for definition of reference values
for GAD antibodies and that comorbidity involving tis-
sues that express GAD needs not be taken into account
when screening for GAD antibodies. Because storage
conditions may significantly affect the outcome of GAD
antibody tests, these need to be monitored meticulously in
collaborative studies.
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